Lanluma is intended to be administrated via injection by a trained and authorized health professional. Opinions and methods presented here are the Physician experience. Refer to instructions for details of specific indications.
*Data on file.
**J Am Acad Dermatol 2010;62:448-62.
NOTICE
Content regarding Lanluma® is not intended for patients and healthcare professionals based in Germany and Spain.
Die Inhalte zu Lanluma® sind nicht für Patienten und Ärzte mit Sitz in Deutschland bestimmt.
El contenido relacionado con Lanluma® no está destinado a pacientes y profesionales sanitarios con sede en España.
NOTICE
Content regarding Lanluma® is not intended for patients and healthcare professionals based in Germany and Spain.
Die Inhalte zu Lanluma® sind nicht für Patienten und Ärzte mit Sitz in Deutschland bestimmt.
El contenido relacionado con Lanluma® no está destinado a pacientes y profesionales sanitarios con sede en España.
INDICATION
Lanluma is a poly-L-lactic acid implant suitable for increasing the volume of depressed areas, particularly to correct skin depressions.
IMPORTANT SAFETY CONSIDERATIONS
Like all procedures of this type there is a possibility of adverse events, although not everybody experiences them. These adverse events include but are not limited to infection, minimal acute inflammatory tissue reaction (redness, swelling, rash, oedema, erythema, lumps/nodules etc.), pain (which may be temporary or persistent in nature), transient haematoma or bruising. For a full list consult Instructions for Use.
The onset of any side effect must be reported immediately. Please contact the local Sinclair representative or authorised Lanluma distributor. Alternatively send the details to Sinclair on: quality@sinclair.com
For a full list of contraindications, warnings and precautions for this product please visit https://www.sinclairpharma.com/eifu for copy of the Product Instructions for Use.
